London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Elrico, do you mean UMG as a partner on Axis? No doubt they would do a good job of it in their home regions but does that not just make them a distributor, the route that we shunned for a global multinational years ago?
clio, agree, umg isn’t good enough but the multinational won’t show until revenue is a lot higher, led up the garden path by sa .
woundcare, we were speaking to about 5 interested parties, apparently could of had a deal then there was just 2, witch sa said he was playing them against each other, and now we are doing it all in-house, costing sbtx money and about 3 years wasted on bull****
Apart from this, I am still a loyal shareholder.
Clio,
Ref UMG. Yes, having a USA partner (Signutra) implies to me that AxisBiotix's pillar would not be too much of a stretch. It would be a strategic move that bypasses India's excessive import taxes. Recent RNSs related to UMG/Dermatonics raise expectations of further collaborative ventures in the near term.
IMHO, UMG is a much better partnership than some investors believe.
Yawn, still no news anybody surprised? Are they still using quill pens in this company, come on guys wake up.
GLA
Farris, you are getting hung up on this revenue point and it isn’t relevant, the important thing for them is conformation we can produce multiple products.
For me the jury is out on UMG being able to push the whole pillar worldwide and it isn’t at the forefront of my mind at the moment, let's see if they can walk before we see if they can run. I am fed up of thinking about things that could happen six or twelve months down the line. I am focused on the CB, Modi forecast & Croda forecast, things that will hopefully happen in the next few weeks and hopefully transform the share price, this is the most important thing. One thing is for sure, if the Modi forecast doesn't come out punching, all this talk of worldwide Axis is a moot point.
Can see how Umesh Modi as a manufacturer and distributer would work for axis, after all with Stuart's inside/out strategic approach to tackling medical conditions such as psoriasis, axis-ps would be a perfect companion to Dermatonic's ultraveen itch relief cream
https://www.google.com/search?q=ultraveen+itch+relief+cream&rlz=1C1VDKB_en-GBGB1103GB1103&oq=ultravee&gs_lcrp=EgZjaHJvbWUqBwgAEAAYgAQyBwgAEAAYgAQyBggBEEUYOTIHCAIQABiABDIHCAMQABiABDIJCAQQABgKGIAEMgkIBRAAGAoYgAQyCQgGEAAYChiABDIJCAcQABgKGIAEMgoICBAAGIAEGKIEMgoICRAAGIAEGKIEqAIIsAIB&sourceid=chrome&ie=UTF-8#ip=1
More immediate, "the imminent" feedback from New Cross Hospital where Once Heel Balm clearly demonstrated it can reduce Heel pressure Ulcers announced as one of the opportunities at 28.40 mins in on t Friday 26th Jan Investor Meets presentation, is now long overdue, and the Amazon USA Once Heel Balm direct launch must be fast approaching too.
Seems like we are awaiting a lot of imminent news, the only problem being is SA up to delivering it?
When is this transformational news coming that was promised back end of 2023? Closing in on Mid-May 2024 and absolutely nothing, overpaid, overrated, taxi for Ashman IMHO.
SP has fallen from 60p - 85% in three years but worry not! CFO is incentivised with massive bonus if the SP reaches 50p!
Baz,
In or under?
Both in & under as I guess most are but the point is that Ashman has not delivered on any timeline that he has shared and the sooner he goes and we get a fresh approach the better the chances are for a recovery IMHO.
Acne is late again as I said before 5 weeks in and news shared in February and 2 1/2 months later and nothing. New funding to sort out his screw up is non existent. Second transformational acquisition by end of Q1, a pipe dream. Sales information, Croda, the list goes on and on and we hear absolutely nothing, a disgrace. He gets played always as he is so weak, we need a stronger CEO who shares meaningful timelines and sticks to them. The CFO is just as bad, neither have a clue how to make this a success. Still both overpaid in spite of taking their back dated pay decrease.
I hope I'm proved wrong and the company is a roaring success but the likelihood of that happening seems to reduce day by day.
RNS 27 February 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that interim data from the AxisBiotix Acne food supplement consumer participant study with the lead formulation are very positive. The Company will continue the study to completion. The analysis and read-out of the final results is anticipated to occur before the end of Q1 2024.
So 5 week update shared end of February, don't know how long it took them to put the results together, let's say 1 week. Trial was for 8 weeks which suggests completion during March. Then we are told they are doing more tranches and will be completed end of April. How difficult is it to add up a few numbers and share the initial results irrespective of what the next plans for it are. If they were brilliant you would expect the board to be falling over themselves to share the news with their shareholders but this pair can't bother to tell us anything. Does this mean the results are not brilliant and they need more work or more time, who knows. The longer it takes for them to share these results the more doubt exists in their performance IMHO.
I know that the Acne trial is not the main pillar of activity but this example of lack of information is indicative of how they operate and the attitude they have to their shareholders IMHO.
Buzz, completely agree, not good enough, I’m holding out for Croda
And even then, no plans announced to sell the lysate ourselves or through a partner. Axisbiotix hyped to hell but one of the worst product launches in history and they still believe a company will make a distribution offer when my local shop sells more pints of milk each month!
I’m a big fan of the potential within this company, but it’s impossible to disagree with you Bazzaman. The team are either letting us down with their lack of successful commercialisation of that potential, or they are simply not bothering to communicate any good work properly with shareholders; the latter being a previous issue and something we have been assured would not continue to happen.
I’m really surprised the board have left shareholders in a position where the SP is languishing in single figures for so long when it should be up at 30,40,50p. It is giving the impression they are helpless and if that’s the case we have to seriously question if their interests align with ours. Their wages are advantageous enough for them even if they achieve nothing.
We’ve been told so many times Croda is out of the control of the board, maybe that’s a good thing looking at how Axis/Acne is being handled. I’m starting to become bemused by the team that tells us they are amazing whilst producing practically nothing tangible. I’m sure I’m not alone in that I have been patient and understanding for a period of years now.
Well, there are buys coming in this morning.
So much buying and only 6% up. Time for the MMs to let this go....
Leaky news around the corner, let's hope so.
It was getting increasingly difficult to buy larger amounts late morning around 9p. Now you can see why with that £32.44K purchase. As you say, might be a bit 'leaky'....
Looks that way, i can't get an online quote for relatively small purchases of £500 at the moment (AJ Bell nor H&L) but can sell larger mounts
Also struggling to get a price for a GBP1000.
Maybe companies buying the lysate are now considering the amount that they need to buy/secure over the coming year and their marketing budget. I am presuming it’s this that is beginning to leak.
Maybe they're pumping it up so they can convert the rest of the CLN's again.
Top Prize goes to leapfrog for the most unlikely reason for SP rise and its notable that 3 people are daft enough to agree with him.